Catalyst Brief

← Calendar

Readoutin 14d

Suven Life Sciences Limited — Masupirdine 50 mg

Phase 3 primary completion: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type.

Date
Dec 2026
Type
Readout
Indication
Agitation

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.